



EXPRESS MAIL NO. EM 490 489 775 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wang et al.

Serial No.: 08/333,680

Group Art Unit: 1804

Filed: November 3, 1994

Examiner: Rories

For: NOVEL ADENOVIRAL VECTORS, Attorney Docket No.: 7639-061
PACKAGING CELL LINES,
RECOMBINANT ADENOVIRUSES,
AND METHODS

AMENDMENT UNDER 37 C.F.R. §1.115

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the outstanding final Office Action dated December 12, 1997, and pursuant to Rule 115 of the Rules of Practice please consider the following amendments and remarks. Applicants submit concurrently herewith (a) an executed Rule 132 Declaration by Dr. Qing Wang; (b) a Supplemental Information Disclosure Statement; and (c) a revised PTO 1449 form listing references AR to AX.

IN THE CLAIMS:

Please amend Claims 39, 41-44, 48-50, 54 and 57 as follows.

For the Examiner's convenience, the unamended claims are reproduced below:

37. (twice amended) A replication-defective recombinant adenovirus, wherein the adenovirus genome contains at least two lethal deletions, two lethal mutations, or one lethal deletion and one lethal mutation in the E1 and E4 early gene